ATE366934T1 - Screening-verfahren von gaba-modulierenden verbindungen für bestimmte pharmakologische wirkungen - Google Patents

Screening-verfahren von gaba-modulierenden verbindungen für bestimmte pharmakologische wirkungen

Info

Publication number
ATE366934T1
ATE366934T1 AT00928860T AT00928860T ATE366934T1 AT E366934 T1 ATE366934 T1 AT E366934T1 AT 00928860 T AT00928860 T AT 00928860T AT 00928860 T AT00928860 T AT 00928860T AT E366934 T1 ATE366934 T1 AT E366934T1
Authority
AT
Austria
Prior art keywords
compounds
properties
gaba
screening method
modulating compounds
Prior art date
Application number
AT00928860T
Other languages
English (en)
Inventor
John Tallman
Dorothy Gallager
Kenneth Shaw
Geoffrey White
Marci Crandall
James Cassella
Lavanya Rajachandran
Pamela Albaugh
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Application granted granted Critical
Publication of ATE366934T1 publication Critical patent/ATE366934T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00928860T 1999-05-07 2000-05-05 Screening-verfahren von gaba-modulierenden verbindungen für bestimmte pharmakologische wirkungen ATE366934T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13319599P 1999-05-07 1999-05-07
US13319199P 1999-05-07 1999-05-07
US13315599P 1999-05-07 1999-05-07
US13315499P 1999-05-07 1999-05-07

Publications (1)

Publication Number Publication Date
ATE366934T1 true ATE366934T1 (de) 2007-08-15

Family

ID=27495014

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00928860T ATE366934T1 (de) 1999-05-07 2000-05-05 Screening-verfahren von gaba-modulierenden verbindungen für bestimmte pharmakologische wirkungen

Country Status (12)

Country Link
EP (1) EP1177445B1 (de)
JP (1) JP2002544487A (de)
AT (1) ATE366934T1 (de)
AU (1) AU4703200A (de)
BR (1) BR0010344A (de)
CA (1) CA2371219A1 (de)
DE (1) DE60035498T2 (de)
DK (1) DK1177445T3 (de)
ES (1) ES2290031T3 (de)
MX (1) MXPA01011353A (de)
PT (1) PT1177445E (de)
WO (1) WO2000068691A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0113697A (pt) 2000-09-06 2003-07-22 Neurogen Corp Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou sal, embalagem e métodos para, para alterar a atividade transdutora de sinal dos receptores de gabaa, para tratar ansiedade, depressão, um distúrbio do sono, ou demência de alzheimer, para demonstrar a presença dos receptores de gabaa em células ou amostras de tecido e para preparar um composto
BR0115874A (pt) * 2000-12-04 2003-10-28 Pfizer Prod Inc Sìntese de pirrole-amidas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597920A (en) * 1992-04-30 1997-01-28 Neurogen Corporation Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes
GB9503601D0 (en) * 1995-02-23 1995-04-12 Merck Sharp & Dohme Method of treatment and method of manufacture of medicament
ATE223576T1 (de) * 1996-10-25 2002-09-15 Neurosearch As Methode zur identifizierung von verbindungen mit anxiolytischem potential

Also Published As

Publication number Publication date
DE60035498T2 (de) 2008-03-13
WO2000068691A1 (en) 2000-11-16
DE60035498D1 (de) 2007-08-23
ES2290031T3 (es) 2008-02-16
EP1177445B1 (de) 2007-07-11
PT1177445E (pt) 2007-10-19
AU4703200A (en) 2000-11-21
EP1177445A1 (de) 2002-02-06
DK1177445T3 (da) 2007-11-05
JP2002544487A (ja) 2002-12-24
CA2371219A1 (en) 2000-11-16
MXPA01011353A (es) 2002-05-06
BR0010344A (pt) 2002-02-19

Similar Documents

Publication Publication Date Title
ATE460668T1 (de) Verfahren zur prognose von brustkrebs mittels quantifizierung von zellulären folat vitamin rezeptoren
ATE430750T1 (de) Kondensierte 4-5-diamino-n,n-dihydro-pyrazol-3-on-derivate und deren verwendung als färbemittel für keratinfasern
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
CO6280567A2 (es) Establecimiento de un anticuerpo monoclonal para detector de proteinas pag en la circulacion
EA200200646A1 (ru) Соединения мочевины, обладающие активностью антагонистов мускариновых рецепторов
BRPI0510170A (pt) antagonistas do receptor muscarìnico de acetilcolina
IT1306704B1 (it) Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
DE60228557D1 (de) Candida-nachweis
Devavry et al. Molecular pharmacology of the mouse melatonin receptors MT1 and MT2
NO960924D0 (no) Analysesett
EA200600267A1 (ru) Антагонисты мускариновых рецепторов ацетилхолина
Cervia et al. Pharmacological characterisation of native somatostatin receptors in AtT‐20 mouse tumour corticotrophs
EA200200732A1 (ru) Замещенные производные фенилпиперазина, их получение и применение
GB2431756B (en) Method and apparatus for automatically evaluating and allocating resources in a cell based system
EA200500830A1 (ru) Производные имидазохинолина в качестве лигандов аденозиновых a3 рецепторов
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
EA200702361A1 (ru) АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
DE60035498D1 (de) Screening-verfahren von gaba-modulierenden verbindungen für bestimmte pharmakologische wirkungen
EA200600787A1 (ru) Антагонисты мускариновых ацетилхолиновых рецепторов
Gilfillan et al. Synthesis and biological evaluation of novel 2, 3-dihydro-1 H-1, 5-benzodiazepin-2-ones; potential imaging agents of the metabotropic glutamate 2 receptor
MY142857A (en) Treatment of incontinence with 5-ht2c receptor agonists
TW200506360A (en) Improved bath analysis
ATE531822T1 (de) Diagnose von prostatakrebs
MXPA04004018A (es) Metodos de separacion por exclusion para toxicidad de compuestos de prueba.
ATE452130T1 (de) 1-(hetero)aryl-3-aminopyrrolidinderivate zur verwendung als antagonisten des mglur3-rezeptors

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee